Ontology highlight
ABSTRACT: Background
Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic.Methodology and principal findings
We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of polymer encapsulated myoblasts engineered to chronically release scFv antibodies targeted against the N-terminus of the A? peptide. Following a 6-month intracerebral therapy we observed a significant reduction of the production and aggregation of the A? peptide in the APP23 transgenic mouse model of Alzheimer's disease. In addition, functional assessment showed prevention of behavioral deficits related to anxiety and memory traits.Conclusions and significance
The chronic local release of antibodies using immunoisolated polymer cell implants represents an alternative passive vaccination strategy in Alzheimer's disease. This novel technique could potentially benefit other diseases presently treated by local and systemic antibody administration.
SUBMITTER: Marroquin Belaunzaran O
PROVIDER: S-EPMC3080361 | biostudies-literature | 2011 Apr
REPOSITORIES: biostudies-literature
Marroquin Belaunzaran Osiris O Cordero Maria Isabel MI Setola Veronica V Bianchi Siro S Galli Carmela C Bouche Nicolas N Mlynarik Vladimir V Gruetter Rolf R Sandi Carmen C Bensadoun Jean-Charles JC Molinari Maurizio M Aebischer Patrick P
PloS one 20110420 4
<h4>Background</h4>Monoclonal antibodies and antibody fragments are powerful biotherapeutics for various debilitating diseases. However, high production costs, functional limitations such as inadequate pharmacokinetics and tissue accessibility are the current principal disadvantages for broadening their use in clinic.<h4>Methodology and principal findings</h4>We report a novel method for the long-term delivery of antibody fragments. We designed an allogenous immunoisolated implant consisting of ...[more]